Petmed Express Inc (NASDAQ:PETS) has been given an average rating of “Hold” by the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $42.80.
Several equities research analysts have weighed in on the stock. ValuEngine upgraded shares of Petmed Express from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Noble Financial restated a “hold” rating on shares of Petmed Express in a research note on Friday, October 27th. BidaskClub downgraded shares of Petmed Express from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 19th. Zacks Investment Research upgraded shares of Petmed Express from a “sell” rating to a “hold” rating and set a $50.00 target price for the company in a research note on Friday, October 20th. Finally, Northcoast Research set a $58.00 target price on shares of Petmed Express and gave the company a “buy” rating in a research note on Wednesday, January 3rd.
Shares of Petmed Express (PETS) opened at $44.06 on Thursday. The firm has a market cap of $903.57, a P/E ratio of 26.07, a price-to-earnings-growth ratio of 2.58 and a beta of 0.95. Petmed Express has a one year low of $19.21 and a one year high of $57.80.
The business also recently declared a quarterly dividend, which will be paid on Friday, February 16th. Shareholders of record on Monday, February 5th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Friday, February 2nd. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.27%. This is a boost from Petmed Express’s previous quarterly dividend of $0.20. Petmed Express’s dividend payout ratio (DPR) is currently 59.17%.
In other Petmed Express news, CEO Menderes Akdag sold 30,000 shares of the firm’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $51.00, for a total value of $1,530,000.00. Following the completion of the transaction, the chief executive officer now owns 490,000 shares of the company’s stock, valued at $24,990,000. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Ronald J. Korn sold 5,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $48.38, for a total transaction of $241,900.00. Following the completion of the transaction, the director now directly owns 68,833 shares of the company’s stock, valued at approximately $3,330,140.54. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,000 shares of company stock valued at $3,229,500. Corporate insiders own 4.00% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of PETS. Sei Investments Co. raised its holdings in shares of Petmed Express by 50,142.9% in the third quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock worth $117,000 after buying an additional 3,510 shares during the last quarter. LS Investment Advisors LLC raised its holdings in shares of Petmed Express by 283.5% in the fourth quarter. LS Investment Advisors LLC now owns 2,861 shares of the company’s stock worth $130,000 after buying an additional 2,115 shares during the last quarter. Sterling Investment Advisors Ltd. raised its holdings in shares of Petmed Express by 118.5% in the fourth quarter. Sterling Investment Advisors Ltd. now owns 2,950 shares of the company’s stock worth $134,000 after buying an additional 1,600 shares during the last quarter. Thompson Siegel & Walmsley LLC purchased a new position in shares of Petmed Express in the third quarter worth $149,000. Finally, CenterStar Asset Management LLC purchased a new position in shares of Petmed Express in the fourth quarter worth $169,000. 96.66% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/15/petmed-express-inc-pets-given-average-rating-of-hold-by-brokerages.html.
Petmed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.